| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | IFNW1; Interferon omega-1; Interferon alpha-II-1 |
| Entrez GeneID | 3467; |
| WB Predicted band size | 22kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the C-terminal region of human IFN-ω. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IFN-ω抗体的模拟参考文献示例(内容为虚构，仅供参考)：
1. **标题**: *"Monoclonal Antibodies Against Interferon Omega: Production and Application in Immunoassays"*
**作者**: Smith A, et al.
**摘要**: 研究团队成功制备了针对IFN-ω的单克隆抗体，并验证其在ELISA和Western blot中的高特异性，为IFN-ω的检测提供了新工具。
2. **标题**: *"Anti-IFN-ω Antibodies in the Pathogenesis of Autoimmune Diseases"*
**作者**: Lee B, et al.
**摘要**: 探讨了系统性红斑狼疮患者体内IFN-ω自身抗体的存在及其与疾病活动的相关性，提示其可能参与免疫失调机制。
3. **标题**: *"Neutralization of IFN-ω by Antibodies Enhances Viral Replication In Vivo"*
**作者**: Garcia C, et al.
**摘要**: 通过动物模型证明，中和IFN-ω的抗体会削弱宿主对RNA病毒(如流感病毒)的防御能力，强调IFN-ω在抗病毒感染中的关键作用。
4. **标题**: *"Engineering a Humanized Anti-IFN-ω Antibody for Therapeutic Use"*
**作者**: Tanaka H, et al.
**摘要**: 报道了一种人源化抗体的开发，该抗体能高效中和IFN-ω并减少慢性炎症模型中的组织损伤，展示了其治疗慢性炎症性疾病的潜力。
---
注：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。如需进一步协助，可提供更具体的研究方向。
Interferon-omega (IFN-ω), a member of the type I interferon family, shares structural and functional similarities with IFN-α and IFN-β but is distinguished by its unique genetic sequence and receptor-binding properties. Primarily produced by leukocytes, IFN-ω exhibits broad antiviral, immunomodulatory, and antiproliferative activities. It signals through the IFN-α/β receptor (IFNAR) complex, activating JAK-STAT pathways to induce interferon-stimulated genes (ISGs) that combat viral replication and regulate immune responses.
Antibodies targeting IFN-ω serve as critical tools for studying its biological roles and therapeutic potential. Monoclonal and polyclonal anti-IFN-ω antibodies are used in immunoassays (e.g., ELISA, Western blot) to detect IFN-ω expression in research or clinical samples. Neutralizing antibodies, which block IFN-ω activity, help elucidate its specific functions in viral infections, autoimmune diseases, or cancer models. For instance, dysregulated IFN-ω signaling has been implicated in autoimmune disorders like systemic lupus erythematosus (SLE), where such antibodies may mitigate pathological inflammation. Additionally, IFN-ω antibodies aid in distinguishing its activity from other type I interferons, addressing cross-reactivity challenges in studies. Recent interest in IFN-ω as a therapeutic agent, particularly for its potent antiviral effects against emerging viruses, has spurred demand for high-specificity antibodies to monitor pharmacokinetics and optimize treatments. Despite limited clinical use compared to IFN-α/β therapeutics, ongoing research highlights IFN-ω's unique immunobiology and the growing utility of its antibodies in both diagnostics and targeted therapies.
×
